TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02346643

Intervention type: DEVICE
Intervention: Implantation with the commercially available Axium Neurostimulator
Study: NCT00066222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m2 given intravenously. During RT, give on day 1 and day 22. After completion of RT, on days 43 and 64.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 120 mg/m2 given intravenously. During RT, give on days 1-3, then days 22-24. After completion of RT, on days 43-45 and days 64-66.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Large field 28.8 Gy: 1.8 Gy per fraction, 5 days per week for 16 fractions. On days 23-26, BID: use anteroposterior and posteroanterior (AP/PA) fields in a.m. at 1.8 Gy per fraction; boost with 2nd treatment in p.m. at 1.8 Gy per fraction. Then off-cord boost, 1.8 Gy, BID, x last 5 days for a total dose of 61.2 Gy in 5 wks.
Study: NCT01469143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Each subject will randomly be allocated to a treatment sequence consisting of 9 dosing visits during which the subject will receive 8 single doses of different formulations. For all investigational medicinal products the dose levels will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: At one of the scheduled visits, the subject will receive a single dose of insulin aspart. The dose level will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
Study: NCT04227795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-Assisted real time colonoscopy
Description: The colonoscopy was performed under artificial intelligence assistance
Study: NCT06094361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iontophoresis Intervention
Description: Iontophoresis was applied with a Chattanooga Physio (DJO Global, Herentals, Belgium) brand device. The galvanic current mode was selected for the intervention. Intervention area was cleaned to prevent irritation and active electrode pad (cathode-5 cm2) was immersed in 75 mg diclofenac sodium solution. The current intensity of the application for 10 minutes was 0.1-0.2 mA/cm2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phonophoresis
Description: Phonophoresis was performed with a Chattanooga brand ultrasound device (Chattanooga, Intelect Legend Ultrasound, TN, USA). 75 mg gel containing 1% diclofenac sodium was applied to the shoulder area. The ultrasound was conducted continuously for 6 minutes with frequency of 1 MHz and an intensity of 1.5 watts/cm2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: All groups received a treatment program consisting of hot pack, Transcutaneous Electrical Nerve Stimulation and Shoulder girdle exercises for 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: All groups received a treatment program consisting of hot pack, Transcutaneous Electrical Nerve Stimulation and Shoulder girdle exercises for 30 minutes.
Study: NCT01208883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: repetitive per-treatment [18F]FDG-PET for treatment adaptation
Description: repetitive per-treatment \[18F\]FDG-PET for treatment adaptation
Study: NCT03455933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Comparator
Description: The investigators will apply a light intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 3/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (3/10 in VAS).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Intervention
Description: The investigators will apply a moderate intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 6/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (6/10 in VAS).

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Patients will place their hand, wide open and up to the wrist, into the inner part of the container and will keep it under water for a maximum time of 2 minutes. If pain is unbearable before the time ends, the participant will be able to withdraw the hand.
Study: NCT00235235

Intervention type: PROCEDURE
Intervention: Biopsy
Description: core biopsy

Intervention type: PROCEDURE
Intervention: Biopsy
Description: core biopsy

Intervention type: PROCEDURE
Intervention: Biopsy
Description: core biopsy

Intervention type: PROCEDURE
Intervention: Biopsy
Description: core biopsy

Intervention type: PROCEDURE
Intervention: Serum Collection
Description: serum collection

Intervention type: PROCEDURE
Intervention: Serum Collection
Description: serum collection

Intervention type: PROCEDURE
Intervention: Serum Collection
Description: serum collection

Intervention type: PROCEDURE
Intervention: Serum Collection
Description: serum collection

Intervention type: PROCEDURE
Intervention: Urine Collection
Description: urine collection

Intervention type: PROCEDURE
Intervention: Urine Collection
Description: urine collection

Intervention type: PROCEDURE
Intervention: Urine Collection
Description: urine collection

Intervention type: PROCEDURE
Intervention: Urine Collection
Description: urine collection

Intervention type: DRUG
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m2 day 1 of every 21-day cycle

Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle

Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle

Intervention type: DRUG
Intervention: Vinorelbine
Description: Vinorelbine 25mg/m2 days 1, 8, 15 of every 28-day cycle

Intervention type: DRUG
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
Study: NCT01188551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine (1 µg/kg) will be administered intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine (1 µg/kg) will be administered intranasally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl (2 µg/kg) will be administered intranasally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl (2 µg/kg) will be administered intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Sedative given pre-op.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Sedative given pre-op.
Study: NCT03743389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12G pigtail catheter
Description: 12G pigtail catheter would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with the traditional 16F chest tube.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 16F chest tube
Description: 16F chest tube would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with 12G pigtail catheter.
Study: NCT01703091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study: NCT04020289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Program BalancingMySwing
Description: Patients in the intervention arm will receive a nurse-lid 8-session psychoeducational 'BalancingMySwing group psychotherapy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychoeducational Program BalancingMySwing
Description: Patients in the intervention arm will receive a nurse-lid 8-session psychoeducational 'BalancingMySwing group psychotherapy
Study: NCT01703091

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered IV
Study: NCT01933698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin
Description: Comparison of pharmacokinetics of both formulations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin
Description: Comparison of pharmacokinetics of both formulations
Study: NCT00801073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human Amniotic Membrane Transplantation
Description: Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
Study: NCT01296711

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038 (olokizumab)
Description: 100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks
Study: NCT01748461

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured intervention
Description: 3x/week - 10 weeks - Support by fitness instructor - Individualised exercise program (cycle ergometer)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coach intervention
Description: promote autonomy - 4 visits during 10 weeks - Support by coach (encouragement) - Individualised exercise program
Study: NCT06264089

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Preservation Rhinoplasty Nasal Valve Angle and Area
Description: The same group of patients who underwent Preservation Rhinoplasty will be followed and the nasal valve angles before and after surgery will be compared.
Study: NCT01326884

Intervention type: DEVICE
Group type: OTHER
Intervention: ZLP
Description: ZLP Graft
Study: NCT00387569

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MnB vaccine rLP8026
Description: MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MnB vaccine rLP8026
Description: MnB vaccine at 60ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MnB vaccine rLP8026
Description: MnB vaccine at 200ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
Study: NCT00883168

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastineHcl
Description: azelastine hydrochloride 548 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: fluticasone propionate 200 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelastine Hcl/fluticasone propionate
Description: azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
Study: NCT02502292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fotonovela
Description: Comparing fotonovela brochure to traditional brochure, as a template communicative behaviors embedded in a picture story where the older people could use before and during primary care consultations with their GP. Relevant communicative behaviors will include 'asking questions', 'expressing lack of or misunderstanding', 'expressing uncertainty', 'expressing preferences and needs' and other relevant communicative behaviors which are based on communication theory / literature and on the output of the focus group discussions.~The researchers will randomly assigned the participants into four groups as described earlier. Mainly to identify the outcomes of the comparison between fotonovela and traditional brochure in both traditional hard-copy and in tablet.
Study: NCT03249909

Intervention type: DEVICE
Group type: OTHER
Intervention: Exufiber Ag+
Description: gelling fibre dressing with silver
Study: NCT01221571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM 13
Description: Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.
Study: NCT01919125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX719
Description: IDX719 supplied as 50 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX719
Description: IDX719 supplied as 50 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX719
Description: IDX719 supplied as 50 mg tablets.
Study: NCT05184244

Intervention type: OTHER
Intervention: Activity Limitation Assessment
Description: The ACTIVLIM-CP scale evaluates the global activity performance and combined movements of the body.
Study: NCT00775424

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX-B
Description: PENNVAX-B is a cocktail of three expression plasmids. The plasmids include the genes which encode a synthetic HIV-1 envelope protein (pEY2E1-B), Gag (gagCAM02), and Pol (pK2C1). Each plasmid is manufactured to a concentration of 4.0 mg/mL and is formulated with bupivacaine (0.25%) as a facilitating agent for DNA uptake. All plasmids (2.0 mg each gag, pol, env) are premixed by the manufacturer in the same vial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX-B
Description: PENNVAX-B is a cocktail of three expression plasmids. The plasmids include the genes which encode a synthetic HIV-1 envelope protein (pEY2E1-B), Gag (gagCAM02), and Pol (pK2C1). Each plasmid is manufactured to a concentration of 4.0 mg/mL and is formulated with bupivacaine (0.25%) as a facilitating agent for DNA uptake. All plasmids (2.0 mg each gag, pol, env) are premixed by the manufacturer in the same vial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX-B
Description: PENNVAX-B is a cocktail of three expression plasmids. The plasmids include the genes which encode a synthetic HIV-1 envelope protein (pEY2E1-B), Gag (gagCAM02), and Pol (pK2C1). Each plasmid is manufactured to a concentration of 4.0 mg/mL and is formulated with bupivacaine (0.25%) as a facilitating agent for DNA uptake. All plasmids (2.0 mg each gag, pol, env) are premixed by the manufacturer in the same vial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GENEVAX IL-12-4532
Description: GENEVAX IL-12-4532 This molecular adjuvant plasmid contains nucleotide sequences necessary for expression of the human IL-12 protein. IL-12 DNA is formulated at a concentration of 2.0 mg/mL with bupivacaine (0.25%).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: PLACEBO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-15 adjuvant
Description: pIL15EAM is a plasmid that encodes human IL-15 and has been optimized to express 87 fold higher than native IL-15 DNA and 5.7 fold higher than an earlier generation optimized IL-15 DNA construct. This plasmid is formulated at a concentration of 4.0 mg/mL with bupivacaine (0.25%).
Study: NCT05000476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye mask and earplugs
Description: Materials similar to those offered on long commercial flights

Intervention type: OTHER
Group type: OTHER
Intervention: Nurse Education and Environmental Regulation
Description: providing orientation to the patient (frequent orientation of the patient to the place, time and person), cognitive stimulation (objects such as clocks and calendars in the patient's field of view), reducing noise and light (minimizing monitors and fluid infusion pump alarms at night), providing early mobilization ( passive-active joint movements, sitting and walking in bed), reducing social deprivation (receiving visitors, telephone calls)
Study: NCT02588443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO70097890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO70097890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Study: NCT06571695

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomic Long Head of Biceps Tensioning Technique
Description: The standard mini-open subpectoral approach will be made. The myotendinous junction of the long head of the biceps tendon and its location within the intertubercular groove will be marked using electrocautery. The surgeon will then turn to the glenohumeral joint and perform the biceps tenotomy.The long head of the biceps tendon will be retrieved.The tendon is tagged with a running, locking number 2 fiberwire suture at the mid substance of the myotendinous junction using the previously made electrocautery marks to set the tension. The tendon is shortened. The sutures from the biceps are passed through the Arthrex cortical button.The pectoralis major tendon is retracted and 2 centimeters proximal to the distal insertion a unicortical bone tunnel is drilled in the bicipital groove with a 3.2 millimeter drill.The wound is irrigated and the biceps button is threaded into this tunnel and then flipped.The suture is tensioned, securing the biceps against the groove

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Long Head of Biceps Tensioning Technique
Description: Diagnostic arthroscopic shoulder scope will occur to assess the long head of the biceps for tendinopathy. Tenotomy will occur at the junction of the supraglenoid tubercle with arthroscopic scissors. Subsequent tensioning and tenodesis will be based on surgeon's preference
Study: NCT03027128

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK™ for Infusion
Description: haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
Study: NCT03786211

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IANB by the guide of Panoramic
Description: IANB will be injected by the guide of panoramic radiograph

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IANB by the guide of Panoramic
Description: IANB will be injected by the guide of panoramic radiograph

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IANB without the guide of Panoramic
Description: IANB will be injected without the guide of panoramic radiograph, in the routine way.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IANB without the guide of Panoramic
Description: IANB will be injected without the guide of panoramic radiograph, in the routine way.
Study: NCT00609050

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Regulated Exercise with Telephone Reinforcement
Description: The self-regulated exercise with telephone reinforcement group will engage in a three-times-a-week (or more) at home exercise regimen for 6 months during which they may choose the mode of exercise. They will receive weekly telephone calls about exercise and airway clearance. After 6 months, they will be instructed to maintain their self-regulated exercise activity for the remaining 6 months of the study, but they will not receive telephone calls

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: The attention control group will receive standard recommendations for exercise activity, during the first 6 months, as is common in our clinic. Also during the first 6 months, they will receive weekly telephone calls about airway clearance. For the final 6 months of the study, the attention control group will cross over to self-regulated exercise without telephone reinforcement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative Approach
Description: A qualitative naturalistic approach is nested within the primary experimental framework to explore the experiences of the children and parents, in both groups, with the exercise regimen.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative Approach
Description: A qualitative naturalistic approach is nested within the primary experimental framework to explore the experiences of the children and parents, in both groups, with the exercise regimen.
Study: NCT04139005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Awareness
Description: The program foundation targets attention and awareness skills that are integral to many conceptions of mindfulness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Awareness
Description: The program foundation targets attention and awareness skills that are integral to many conceptions of mindfulness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connection
Description: The Connection module targets skills underlying social connection, which refers to the sense of having close and positively experienced relationships with others in the social world.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insight
Description: The Insight module targets skills underlying dynamic self-inquiry and experiential self-knowledge.
Study: NCT00800579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9411
Description: Inhaled GS-9411 dissolved in sterile saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9411
Description: Inhaled GS-9411 dissolved in sterile saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9411
Description: Inhaled GS-9411 dissolved in sterile saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled volume-matched placebo in sterile saline
Study: NCT00168415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 100 U up to 6 times during the study depending on the response to treatment
Study: NCT05090488

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personal Health Coaching and Diabetes Education in Group
Description: Health coaching was given as face to face with a trained coach from primary health care. Diabetes education in group, with trained educator team from primary health care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Health Coaching and Diabetes Education in Group
Description: Health coaching was given as face to face with a trained coach from primary health care. Diabetes education in group, with trained educator team from primary health care